Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
|Articles|January 27, 2020
Bioavailability and Development Toolkit
Author(s)Catalent
With global development and manufacturing sites, Catalent combines its formulation and bioavailability enhancement experience, along with delivery technologies to support the launch of more than 100 new products every year.
From its early-phase drug development centres of excellence in Nottingham, United Kingdom, Somerset, NJ, and San Diego, CA, and network of manufacturing facilities, Catalent offers partners end-to-end solutions, encompassing early drug product formulation and dose form design, through to clinical supply, commercial-scale manufacturing and lifecycle management.
For early development, these solutions include analytical, pre-formulation, and formulation technologies, and a comprehensive bioavailability enhancing technology toolkit including lipid formulation, spray drying, and hot melt extrusion. Its experience sees Catalent support the development and launch of over 100 new products every year.
By adapting for each molecule’s unique characteristics and challenges, Catalent uses its experience and a wide range of tools and technologies to create dose forms that benefit patients.
Catalent’s multi-award-winning OptiForm Solution Suite platform can assist in the development of innovative dose forms that can improve a drug’s efficacy and success. OptiForm Solution Suite is fast, flexible, and fact-based, combining the broadest selection of enabling technologies to ensure the right decisions are made at each stage of development.
Related to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
3
AAPS PharmSci 360 2026: E&L Standards Harmonization
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5